Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 3/20 | 0.43 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.43 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.43 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8803578 | 0.89 | AGTR1 (0.55) | AGTR1TBXA2RAGTR2PDE3A | |
| SCHEMBL8803987 | 0.88 | AGTR1 (0.56) | AGTR1TBXA2RAGTR2PDE3A | |
| SCHEMBL7428240 | 0.81 | AGTR1 (0.54) | AGTR1TBXA2RAGTR2PDE3A | |
| SCHEMBL8803999 | 0.77 | AGTR1 (0.59) | AGTR1TBXA2RAGTR2PDE3A | |
| Tasosartan SCHEMBL49626 | 0.76 | AGTR1 (0.71) | AGTR1TBXA2RAGTR2PDE3A | |
| SCHEMBL683802 | 0.73 | AGTR1 (0.50) | AGTR1TBXA2RAGTR2PDE3A | |
| SCHEMBL7426784 | 0.72 | AGTR1 (0.49) | AGTR1TBXA2RAGTR2PDE3A | |
| SCHEMBL683800 | 0.72 | AGTR1 (0.55) | AGTR1TBXA2RAGTR2PDE3A | |
| Water SCHEMBL7438445 | 0.72 | AGTR1 (0.49) | AGTR1TBXA2RAGTR2PDE3A | |
| SCHEMBL7429405 | 0.71 | AGTR1 (0.61) | AGTR1TBXA2RAGTR2PDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110046090-A1 | MODULATION OF NEUROGENESIS WITH GABA AGENTS AND GABA ANALOGS | BRAINCELLS INC. (US) | 2011-02-24 | — | — | US | disclosed |
| US-20110046090-A1 | MODULATION OF NEUROGENESIS WITH GABA AGENTS AND GABA ANALOGS | BRAINCELLS INC. (US) | 2011-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046090-A1 | MODULATION OF NEUROGENESIS WITH GABA AGENTS AND GABA ANALOGS | GAP43, GABRB1, GABRB3 | AGTR1 3252/4885TBXA2R 442/4885AGTR2 2610/4885 |
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | NGF, DCX, BDNF | AGTR1 8/4885TBXA2R 1092/4885AGTR2 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.